CONTEXT: Neurotoxic beta-amyloid accumulates in regions of the brain affected by advanced Alzheimer's disease. It is a suspected contributor to the development of the condition.
RESULTS: Dr. Jorge Barrio and researchers from the University of California, Los Angeles demonstrated that F-18 FDDNP microPET can visualize b-amyloid load in vivo in the brains of transgenic mice. Dynamic scans with the agent were performed on three experimental and two control animals. FDDNP uptake was elevated in the cerebral cortex, most prominently in the frontal lobe and hippocampal regions of the experimental transgenic mice (p = 0.001). Only background cortical binding was seen in control subjects. Results were consistent with previous in vitro results with b-amyloid neurofibrils and brain specimens of Alzheimer's disease patients. They were presented at the 2005 Academy of Molecular Imaging meeting.
IMPLICATIONS: The ability to quantify beta-amyloid plaque load could identify healthy adults who are suspicious for the future development of AD and could play a role in monitoring the effect of anti-amyloid therapies.
AI Algorithm Comparable to Radiologists in Differentiating Small Renal Masses on CT
May 14th 2024An emerging deep learning algorithm had a lower AUC and sensitivity than urological radiologists for differentiating between small renal masses on computed tomography (CT) scans but had a 21 percent higher sensitivity rate than non-urological radiologists, according to new research.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.